Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Crystal L Mackall"'
Autor:
Audrey Mauguen, Snehit Prabhu, Christine L Phillips, Kevin J. Curran, Michael Kunicki, Prakash Satwani, Theodore W. Laetsch, Rachel Wilcox, Muna Qayed, Vasant Chinnabhandar, Crystal L. Mackall, Steven P. Margossian, Michael R. Verneris, Michelle L. Hermiston, Vanessa A Fabrizio, Christina Baggott, Julie-An An Talano, Emily Egeler, Gary Doug Myers, A. Yasemin Goksenin, Amy Moskop, Cara A Rabik, Holly L Pacenta, Amy K. Keating, Jenna Rossoff, Christa Krupski, Heather E. Stefanski, Patrick A. Brown, Nicole Karras, Jaap Jan Boelens, Sharon Mavroukakis, Liora M. Schultz
Publikováno v:
Blood advances, vol 6, iss 7
Chimeric antigen receptor (CAR) T cells provide a therapeutic option in hematologic malignancies. However, treatment failure after initial response approaches 50%. In allogeneic hematopoietic cell transplantation, optimal fludarabine exposure improve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fab5a5590ca98bdc6c2ccd6b052b9feb
https://escholarship.org/uc/item/6xt142fk
https://escholarship.org/uc/item/6xt142fk
Autor:
Johanna Theruvath, Marie Menard, Benjamin A. H. Smith, Miles H. Linde, Garry L. Coles, Guillermo Nicolas Dalton, Wei Wu, Louise Kiru, Alberto Delaidelli, Elena Sotillo, John L. Silberstein, Anna C. Geraghty, Allison Banuelos, Molly Thomas Radosevich, Shaurya Dhingra, Sabine Heitzeneder, Aidan Tousley, John Lattin, Peng Xu, Jing Huang, Nicole Nasholm, Andy He, Tracy C. Kuo, Emma R. B. Sangalang, Jaume Pons, Amira Barkal, Rachel E. Brewer, Kristopher D. Marjon, Jose G. Vilches-Moure, Payton L. Marshall, Ricardo Fernandes, Michelle Monje, Jennifer R. Cochran, Poul H. Sorensen, Heike E. Daldrup-Link, Irving L. Weissman, Julien Sage, Ravindra Majeti, Carolyn R. Bertozzi, William A. Weiss, Crystal L. Mackall, Robbie G. Majzner
Publikováno v:
Nature medicine, vol 28, iss 2
Nat Med
Nat Med
The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal antibodies targeting GD2 have substantially improved outcomes for children with high-risk neuroblastoma. However, approximately 40% of patients with neuroblastoma sti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aad3910b686c28eafa24813f728551c
https://escholarship.org/uc/item/5nz6n240
https://escholarship.org/uc/item/5nz6n240
Autor:
Michael Kunicki, Sharon Mavroukakis, Cara A Rabik, Christine L Phillips, Amy K. Keating, Jenna Rossoff, Christa Krupski, Rachel Wilcox, Amy Moskop, Adam Lane, Nicole Karras, Kevin J. Curran, A. Yasemin Goksenin, Crystal L. Mackall, Vasant Chinnabhandar, Emily Egeler, Heather E. Stefanski, Michelle L. Hermiston, Julie-An An Talano, Theodore W. Laetsch, Gary Doug Myers, Prakash Satwani, Snehit Prabhu, Christina Baggott, Steven P. Margossian, Patrick A. Brown, Muna Qayed, Vanessa A Fabrizio, Holly L Pacenta, Michael R. Verneris, Liora M. Schultz
Publikováno v:
Blood Advances
Key Points CD19 CAR therapy for R/R EM disease, particularly CNS, offers a beneficial option with similar toxicity and survival to BM disease.There was no increased cytokine release syndrome or neurotoxicity in patients with R/R EM disease, including
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5643a68fa7ec55f29728456a9d6f1876
https://escholarship.org/uc/item/1g83m8ch
https://escholarship.org/uc/item/1g83m8ch